159 related articles for article (PubMed ID: 20473926)
1. Soluble E-cadherin as a serum biomarker candidate: elevated levels in patients with late-stage colorectal carcinoma and FAP.
Weiss JV; Klein-Scory S; Kübler S; Reinacher-Schick A; Stricker I; Schmiegel W; Schwarte-Waldhoff I
Int J Cancer; 2011 Mar; 128(6):1384-92. PubMed ID: 20473926
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of serum soluble E-cadherin in colorectal carcinoma.
Okugawa Y; Toiyama Y; Inoue Y; Iwata T; Fujikawa H; Saigusa S; Konishi N; Tanaka K; Uchida K; Kusunoki M
J Surg Res; 2012 Jun; 175(2):e67-73. PubMed ID: 22277332
[TBL] [Abstract][Full Text] [Related]
3. Circulating midkine in malignant and non-malignant colorectal diseases.
Krzystek-Korpacka M; Diakowska D; Neubauer K; Gamian A
Cytokine; 2013 Oct; 64(1):158-64. PubMed ID: 23899719
[TBL] [Abstract][Full Text] [Related]
4. Elevated soluble E-cadherin during the epithelial-mesenchymal transition process and as a diagnostic marker in colorectal cancer.
Zhu S; Zhao G; Zhao X; Zhan X; Cai M; Geng C; Pu Q; Zhao Q; Fu Q; Huang C; Wang Q
Gene; 2020 Sep; 754():144899. PubMed ID: 32544494
[TBL] [Abstract][Full Text] [Related]
5. Serum Cyr61 as a potential biomarker for diagnosis of colorectal cancer.
Song YF; Xu ZB; Zhu XJ; Tao X; Liu JL; Gao FL; Wu CL; Song B; Lin Q
Clin Transl Oncol; 2017 Apr; 19(4):519-524. PubMed ID: 27743169
[TBL] [Abstract][Full Text] [Related]
6. Serum macrophage-colony stimulating factor levels in colorectal cancer patients correlate with lymph node metastasis and poor prognosis.
Mroczko B; Groblewska M; Wereszczyńska-Siemiatkowska U; Okulczyk B; Kedra B; Łaszewicz W; Dabrowski A; Szmitkowski M
Clin Chim Acta; 2007 May; 380(1-2):208-12. PubMed ID: 17368603
[TBL] [Abstract][Full Text] [Related]
7. Soluble E-cadherin is a valid prognostic marker in gastric carcinoma.
Chan AO; Lam SK; Chu KM; Lam CM; Kwok E; Leung SY; Yuen ST; Law SY; Hui WM; Lai KC; Wong CY; Hu HC; Lai CL; Wong J
Gut; 2001 Jun; 48(6):808-11. PubMed ID: 11358900
[TBL] [Abstract][Full Text] [Related]
8. Detection of cadherin-17 in human colon cancer LIM1215 cell secretome and tumour xenograft-derived interstitial fluid and plasma.
Bernhard OK; Greening DW; Barnes TW; Ji H; Simpson RJ
Biochim Biophys Acta; 2013 Nov; 1834(11):2372-9. PubMed ID: 23557862
[TBL] [Abstract][Full Text] [Related]
9. Soluble CXCL16 in preoperative serum is a novel prognostic marker and predicts recurrence of liver metastases in colorectal cancer patients.
Matsushita K; Toiyama Y; Tanaka K; Saigusa S; Hiro J; Uchida K; Inoue Y; Kusunoki M
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S518-27. PubMed ID: 21845497
[TBL] [Abstract][Full Text] [Related]
10. Serum hepatocyte growth factor as a prognostic marker for stage II or III colorectal cancer patients.
Toiyama Y; Miki C; Inoue Y; Okugawa Y; Tanaka K; Kusunoki M
Int J Cancer; 2009 Oct; 125(7):1657-62. PubMed ID: 19569242
[TBL] [Abstract][Full Text] [Related]
11. The expression of E-cadherin and catenins in colorectal tumours from familial adenomatous polyposis patients.
El-Bahrawy MA; Talbot IC; Poulsom R; Jeffery R; Alison MR
J Pathol; 2002 Sep; 198(1):69-76. PubMed ID: 12210065
[TBL] [Abstract][Full Text] [Related]
12. An elevated preoperative serum carbohydrate antigen 19-9 level is a significant predictor for peritoneal dissemination and poor survival in colorectal cancer.
Takakura Y; Ikeda S; Imaoka Y; Urushihara T; Itamoto T
Colorectal Dis; 2015 May; 17(5):417-25. PubMed ID: 25512077
[TBL] [Abstract][Full Text] [Related]
13. sE-cadherin serves as a diagnostic and predictive parameter in prostate cancer patients.
Tsaur I; Thurn K; Juengel E; Gust KM; Borgmann H; Mager R; Bartsch G; Oppermann E; Ackermann H; Nelson K; Haferkamp A; Blaheta RA
J Exp Clin Cancer Res; 2015 May; 34(1):43. PubMed ID: 25967040
[TBL] [Abstract][Full Text] [Related]
14. Comparative analysis of predictive biomarkers for therapeutical strategies in colorectal cancer.
Gasser M; Gerstlauer C; Grimm M; Bueter M; Lebedeva T; Lutz J; Maeder U; Ribas C; Ribas C; Nichiporuk E; Thalheimer A; Heemann U; Thiede A; Meyer D; Waaga-Gasser AM
Ann Surg Oncol; 2007 Apr; 14(4):1272-84. PubMed ID: 17211733
[TBL] [Abstract][Full Text] [Related]
15. Soluble serum E-cadherin as a marker of tumour progression in colorectal cancer patients.
Wilmanns C; Grossmann J; Steinhauer S; Manthey G; Weinhold B; Schmitt-Gräff A; von Specht BU
Clin Exp Metastasis; 2004; 21(1):75-8. PubMed ID: 15065605
[TBL] [Abstract][Full Text] [Related]
16. The extracellular domain of E cadherin linked to invasiveness in colorectal cancer: a new resistance and relapses monitoring serum-bio marker?
Christou N; Perraud A; Blondy S; Jauberteau MO; Battu S; Mathonnet M
J Cancer Res Clin Oncol; 2017 Jul; 143(7):1177-1190. PubMed ID: 28289897
[TBL] [Abstract][Full Text] [Related]
17. Serum angiogenin as a potential biomarker for early detection of colorectal adenomas and colorectal cancer.
Yu D; Sun J; Weng Y; Luo L; Sheng J; Xu Z
Anticancer Drugs; 2021 Aug; 32(7):703-708. PubMed ID: 33661188
[TBL] [Abstract][Full Text] [Related]
18. Plasma TIMP-1 and CEA as Markers for Detection of Primary Colorectal Cancer: A Prospective Validation Study Including Symptomatic and Non-symptomatic Individuals.
Christensen IJ; Brünner N; Dowell B; Davis G; Nielsen HJ; Newstead G; King D
Anticancer Res; 2015 Sep; 35(9):4935-41. PubMed ID: 26254391
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of microRNAs-29a, 92a and 145 in colorectal carcinoma as candidate diagnostic markers: An Egyptian pilot study.
Ramzy I; Hasaballah M; Marzaban R; Shaker O; Soliman ZA
Clin Res Hepatol Gastroenterol; 2015 Sep; 39(4):508-15. PubMed ID: 25736690
[TBL] [Abstract][Full Text] [Related]
20. Serum interleukin 6 (IL-6) and C-reactive protein (CRP) levels in colorectal adenoma and cancer patients.
Groblewska M; Mroczko B; Wereszczyńska-Siemiatkowska U; Kedra B; Lukaszewicz M; Baniukiewicz A; Szmitkowski M
Clin Chem Lab Med; 2008; 46(10):1423-8. PubMed ID: 18844497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
